• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Mcclain Sean covered exercise/tax liability with 16,991 shares, decreasing direct ownership by 0.21% to 8,194,421 units (SEC Form 4)

    2/4/25 4:31:31 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    McClain Sean

    (Last) (First) (Middle)
    C/O ABSCI CORPORATION
    18105 SE MILL PLAIN BLVD

    (Street)
    VANCOUVER WA 98683

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Absci Corp [ ABSI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/01/2025 F 16,991(1) D $3.71 8,194,421 D
    Common Stock 2,269,987 I See footnote(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares of Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units.
    2. These shares are held by Brittany McClain and are subject to a voting agreement and proxy pursuant to which the Reporting Person is entitled to vote such shares on all matters presented to the Issuer's stockholders for approval. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, if any.
    Remarks:
    /s/ Shelby Walker, attorney-in-fact 02/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ABSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    5/4/2023$4.00Buy
    H.C. Wainwright
    8/12/2022Overweight → Underweight
    JP Morgan
    7/18/2022$8.00Buy
    Truist
    More analyst ratings

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Absci Corporation with a new price target

      Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

      1/22/25 7:30:02 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Guggenheim initiated coverage on Absci Corporation with a new price target

      Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00

      10/2/24 7:13:36 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Morgan Stanley initiated coverage on Absci Corporation with a new price target

      Morgan Stanley initiated coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

      7/3/24 7:24:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

      Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

      1/10/24 7:30:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

      VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a

      6/6/23 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Welcomes Meta Senior Executive to Board of Directors

      VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the newest member of its Board of Directors. With three decades of leadership in scaling technologies, innovating business models and growing companies, Mr. Rabinovitsj will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster. "Absci has impressed me with their technology and data, together which have the potential to turn Absci's bold vision into reality: to create therapeutics at a

      11/2/22 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Participate in Upcoming Investor Conferences

      VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time 24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time Interested parties may access live and archived webcasts of the fireside chat sessions on the company's

      3/26/25 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Financials

    Live finance-specific insights

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

      VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available fo

      3/4/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Redmile Group, Llc bought $999,999 worth of shares (222,222 units at $4.50) (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/5/24 9:30:43 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation

      SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)

      5/12/25 10:24:40 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Absci Corporation

      SCHEDULE 13D/A - Absci Corp (0001672688) (Subject)

      4/29/25 9:31:04 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by Absci Corporation

      DEFA14A - Absci Corp (0001672688) (Filer)

      4/28/25 4:13:02 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Walker Shelby J. was granted 59,300 shares (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:43:06 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SVP, CAO Bedrick Todd was granted 29,700 shares, increasing direct ownership by 22% to 167,827 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:42:16 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chief Executive Officer Mcclain Sean was granted 190,200 shares, increasing direct ownership by 2% to 8,384,621 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:41:15 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Absci Corporation

      SC 13G - Absci Corp (0001672688) (Subject)

      11/14/24 4:02:50 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Absci Corporation

      SC 13G/A - Absci Corp (0001672688) (Subject)

      11/12/24 9:50:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Absci Corporation (Amendment)

      SC 13D/A - Absci Corp (0001672688) (Subject)

      3/5/24 5:15:30 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care